Search Results

Treatment and prophylaxis of hematologic malignancy in the central nervous system.

• Authors : Nagpal S; Stanford Cancer Center, 875 Blake Wilbur Drive CC2221, Stanford, CA, 94305, USA.; Recht L

• Source: Current treatment options in neurology [Curr Treat Options Neurol] 2011 Aug; Vol. 13 (4), pp. 400-12.Publisher: Springer US Country of Publication: United States NLM ID: 9815940 Publication Model: Print Cited Medium: Internet ISSN: 1534-3138

Record details

Is single-agent temozolomide the treatment of choice for recurrent primary central nervous system lymphoma?

• Authors : Omuro AM; Division de Neurologie, Groupe Hospitalier, Pitié-Salpêtrière, Mazarin 47, Paris, France.

• Source: Nature clinical practice. Oncology [Nat Clin Pract Oncol] 2007 Sep; Vol. 4 (9), pp. 514-5. Date of Electronic Publication: 2007 Jul 10.Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101226509 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Temozolomide as salvage treatment in primary brain lymphomas.

• Authors : Reni M; Medical Oncology Unit, Department of Oncology, San Raffaele Scientific Institute, Milan, Italy. ; Zaja F

Subjects: Salvage Therapy*; Antineoplastic Agents, Alkylating/Antineoplastic Agents, Alkylating/Antineoplastic Agents, Alkylating/*administration & dosage ; Brain Neoplasms/Brain Neoplasms/Brain Neoplasms/*drug therapy

• Source: British journal of cancer [Br J Cancer] 2007 Mar 26; Vol. 96 (6), pp. 864-7. Date of Electronic Publication: 2007 Feb 27.Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited

Record details